All In MedTech

Device Trial Radar · NCT07339384

Signatera Assessment in Early-Stage Endometrial Cancer

Circulating Tumor DNA Assessment in Early-Stage Endometrial Cancer (SIGNAL-EMC 101)

Last checked: Nov 20, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 1,010 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

1,010

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Oct 2034

Study completion Oct 2034

Sponsor

Lead sponsor
Natera, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jan 14, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess if circulating tumor DNA can guide adjuvant selection in high-intermediate risk early-stage endometrial cancer. The main question it aims to answer is: • To evaluate if 3-year recurrence-free survival among women with Stage I, high-intermediate risk endometrial cancer who are ctDNA negative after receiving ctDNA-guided observation is non-inferior to adjuvant vaginal brachytherapy (an internal radiation therapy) Researchers will compare high-risk intermediate ctDNA negative participants who are observed to those who receive vaginal brachytherapy to see if they have similar outcomes. Participants will be asked to: * Receive serial ctDNA testing * Visit their study doctor per their standard of care visits about every 3 months for 2 years * Answer a questionnaire about their well-being

Conditions

  • Endometrial Cancer

Interventions

  • Signatera Genome ultra-sensitive ctDNA blood testDevice

    Signatera Genome is intended for use as a post-surgical risk stratification tool for patients with early-stage HIR endometrial cancer. The test is used to identify patients with no evidence of MRD following definitive surgery.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Recurrence Free Survival (RFS)Time frame: 3 years from randomization to the first occurrence of disease recurrence or death from any cause, whichever occurs first

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Hospital

    Birmingham, Alabama

  • University of California, San Diego

    La Jolla, California

  • University of California, Los Angeles

    Los Angeles, California

9 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.